Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of common stock of NeoGenomics, Inc. by the selling stockholder, GE Medical Systems Information Technologies, Inc.
Morgan Stanley acted as sole Bookrunner on the offering
The common stock is listed on the NASDAQ Global Select Market under the symbol “NEO.”
NeoGenomics specializes in cancer genetics testing and information services. NeoGenomics provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. NeoGenomics’ Pharma Services division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks and managed care organizations throughout the United States.
The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Ferrell Maguire Keel and Virginia J. Clarke. The intellectual property and technology team included partner Frank J. Azzopardi and associates Christopher C. Woller and Yifu Chen. Partner Michael Farber and associate Yixuan Long provided tax advice.
Involved fees earner: Frank Azzopardi – Davis Polk & Wardwell; Yifu Chen – Davis Polk & Wardwell; Virginia Clarke – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Yixuan Long – Davis Polk & Wardwell; Ferrell Maguire Keel – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell;
Law Firms: Davis Polk & Wardwell;
Clients: Morgan Stanley;